Cardiff Oncology
CRDF
77 hedge funds and large institutions have $45.8M invested in Cardiff Oncology in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 6 closing their positions.
1,335% more call options, than puts
Call options by funds: $4.67M | Put options by funds: $325K
485% more capital invested
Capital invested by funds: $7.84M → $45.8M (+$38M)
367% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 6
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
40% more funds holding
Funds holding: 55 → 77 (+22)
7.4% more ownership
Funds ownership: 11.85% → 19.25% (+7.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.82M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.15M |
| 3 |
Goldman Sachs
New York
|
+$760K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$672K |
| 5 |
BC
BIT Capital
Berlin,
Germany
|
+$628K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$104K |
| 2 |
Renaissance Technologies
New York
|
-$80.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$73.8K |
| 4 |
EP
Elkhorn Partners
Omaha,
Nebraska
|
-$70.4K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$49.5K |
CRDF Hedge Fund Activity: Q1 2024 in Review
77 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q1 2024, worth a combined $45.8M — up 485% from $7.84M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CRDF positions and 6 closed out — a net gain of 22 holders — while 17 added to existing stakes and 10 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.82M. The largest seller was BlackRock, cutting an estimated $104K.
- 77 institutional investors held Cardiff Oncology (CRDF) as of Q1 2024, up from 55 in Q4 2023.
- Funds reported $45.8M of Cardiff Oncology stock for Q1 2024, up 485% quarter-over-quarter.
- 28 funds opened new Cardiff Oncology positions in Q1 2024 and 6 closed out, a net change of +22 holders.
- The largest Cardiff Oncology buyer in Q1 2024 was Millennium Management, an estimated $1.82M added.
- The largest Cardiff Oncology seller in Q1 2024 was BlackRock, an estimated $104K sold.
Based on aggregated 13F filings for Q1 2024.